Literature DB >> 18287411

Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations.

Stephen N Wong1, Chun-Jung Lin, Chen-Chun Lin, Wei-Ting Chen, Ian Homer Y Cua, Shi-Ming Lin.   

Abstract

OBJECTIVE: The purpose of this study was to investigate whether combining percutaneous ethanol injection (PEI) with radiofrequency ablation in the management of hepatocellular carcinoma (HCC) in high-risk locations improves treatment outcomes. SUBJECTS AND METHODS: We compared the outcome of management of high-risk tumors with PEI and radiofrequency ablation (n = 50) or radiofrequency ablation alone (n = 114) with the outcome of radiofrequency ablation of non-high-risk tumors (n = 44). We also compared the survival rates of patients with and those without high-risk HCC. PEI was performed into the part of the tumor closest to a blood vessel or vital structure before radiofrequency ablation.
RESULTS: The study included 142 patients with 208 HCCs managed with radiofrequency ablation. Despite larger tumor sizes (2.8 +/- 1 cm vs 1.9 +/- 0.7 cm vs 2.5 +/- 0.1 cm for the high-risk radiofrequency plus PEI, non-high-risk radiofrequency, and high-risk radiofrequency groups, respectively; p < 0.001), the primary effectiveness rate of high-risk radiofrequency ablation and PEI (92%) was similar to that of non-high-risk radiofrequency ablation (96%). The primary effectiveness rate of high-risk radiofrequency ablation and PEI was slightly higher (p = 0.1) than that of high-risk radiofrequency ablation (85%). The local tumor progression rates (21% vs 33% vs 24% at 18 months) of the three respective groups were not statistically different (p = 0.91). Patients with and those without high-risk tumors had equal survival rates (p = 0.42) after 12 (87% vs 100%) and 24 (77% vs 80%) months of follow-up. Independent predictors of primary effectiveness were a tumor size of 3 cm or less (p = 0.01) and distinct tumor borders (p = 0.009). Indistinct borders (p = 0.033) and non-treatment-naive status of HCC (p = 0.002) were associated with higher local tumor progression rates. The only predictor of survival was complete ablation of all index tumors (p = 0.001).
CONCLUSION: The combination of radiofrequency ablation and PEI in the management of HCC in high-risk locations has a slightly higher primary effectiveness rate than does radiofrequency ablation alone. A randomized controlled study is warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18287411     DOI: 10.2214/AJR.07.2537

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  25 in total

1.  Application of the Barcelona Clinic Liver Cancer therapeutic strategy and impact on survival.

Authors:  Manuel Hernández-Guerra; Alejandro Hernández-Camba; Juan Turnes; Luis Martin Ramos; Laura Arranz; José Mera; Javier Crespo; Enrique Quintero
Journal:  United European Gastroenterol J       Date:  2015-06       Impact factor: 4.623

2.  Radiofrequency ablation for hepatocellular carcinoma: use of low vs maximal radiofrequency power.

Authors:  T C Macatula; C-C Lin; C-J Lin; W-T Chen; S-M Lin
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

3.  Role of contrast-enhanced ultrasound in follow-up assessment after ablation for hepatocellular carcinoma.

Authors:  Shu-Guang Zheng; Hui-Xiong Xu; Ming-De Lu; Xiao-Yan Xie; Zuo-Feng Xu; Guang-Jian Liu; Lin-Na Liu
Journal:  World J Gastroenterol       Date:  2013-02-14       Impact factor: 5.742

Review 4.  Radiofrequency ablation-combined multimodel therapies for hepatocellular carcinoma: Current status.

Authors:  Lumin Chen; Jihong Sun; Xiaoming Yang
Journal:  Cancer Lett       Date:  2015-10-22       Impact factor: 8.679

5.  Adequacy and quality of abdominal echographies requested by primary care professionals.

Authors:  Ma Antònia Auladell; Llorenç Caballeria; Guillem Pera; Lluís Rodríguez; José Dario Casas; Jesús Aznar; Dolores Miranda; Carmen Sánchez; Antonio Negrete; Josep Ma Castellví; Jesús Bernad; Santiago Canut; Josep Aubà; Miren Maite Aizpurua; Pere Torán
Journal:  BMC Gastroenterol       Date:  2010-09-06       Impact factor: 3.067

Review 6.  Local ablation for hepatocellular carcinoma in taiwan.

Authors:  Shi-Ming Lin
Journal:  Liver Cancer       Date:  2013-04       Impact factor: 11.740

Review 7.  Hepatocellular carcinoma: From diagnosis to treatment.

Authors:  Abhijeet Waghray; Arvind R Murali; Kv Narayanan Menon
Journal:  World J Hepatol       Date:  2015-05-18

8.  Radiofrequency ablation or percutaneous ethanol injection for the treatment of liver tumors.

Authors:  Daniel Ansari; Roland Andersson
Journal:  World J Gastroenterol       Date:  2012-03-14       Impact factor: 5.742

9.  Long-term outcomes and prognostic analysis of radiofrequency ablation for small hepatocellular carcinoma: 10-year follow-up in Chinese patients.

Authors:  Lan Zhang; Ning-Lin Ge; Yi Chen; Xiao-Ying Xie; Xin Yin; Yu-Hong Gan; Bo-Heng Zhang; Ju-Bo Zhang; Rong-Xin Chen; Yan-Hong Wang; Sheng-Long Ye; Zheng-Gang Ren
Journal:  Med Oncol       Date:  2015-02-20       Impact factor: 3.064

10.  Combination therapy consisting of ethanol and radiofrequency ablation for predominantly cystic thyroid nodules.

Authors:  H M Yoon; J H Baek; J H Lee; E J Ha; J K Kim; J H Yoon; W B Kim
Journal:  AJNR Am J Neuroradiol       Date:  2013-08-22       Impact factor: 3.825

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.